In the News

Web Exclusives | February 22, 2019
On February 15, 2019, the US Food and Drug Administration (FDA) approved the immunotherapy agent pembrolizumab (Keytruda; Merck) for the adjuvant treatment of patients with resected stage III melanoma. This was the fourth approval pembrolizumab has received in the United States for the treatment of skin cancer, and the first FDA approval in the adjuvant setting.
News and Updates | February 1, 2019
  • FDA Approves First Therapy for the Treatment of Adult Patients with a Rare Blood Clotting Disorder
  • FDA Issues Letter to Healthcare Providers Alerting Them to a Risk for Breast Implant Associated–Anaplastic Large-Cell Lymphoma
News and Updates | February 1, 2019
  • FDA Resumes Operations After Government Shutdown Ends
  • FDA Approves New Drug Indication for Use in Hepatocellular Carcinoma
  • FDA Approves Pembrolizumab for Merkel-Cell Carcinoma
News and Updates | January 15, 2019
Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold.
May 2018 Vol 9, No 5 | May 22, 2018
The Biden Cancer Initiative builds on former Vice President Joe Biden’s work on the National Cancer Moonshot Initiative by developing and driving implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes.
May 2018 Vol 9, No 5 | May 22, 2018
“Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.” –Danelle Johnston, MSN, RN, ONN-CG, OCN
May 2018 Vol 9, No 5 | May 22, 2018
Federal health officials this week allowed a genetic testing firm to sell kits to consumers to test whether they carry gene mutations that put them at higher risk for breast and ovarian cancer.
March 2018 Vol 9, No 3 | March 15, 2018
"Our partnership with AONN+ is a great addition to the tools and resources Midwest Cancer Alliance offers our medical colleagues.” –Executive Director, Hope Krebill, MSW, BSN, RN
It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American Cancer Society (ACS) recently validated when they entered into a National Alliance Partnership Program.
February 2012 Vol 3, No 1 | February 26, 2012
People within the Johns Hopkins community have long known that Lillie Shockney is an amazing nurse.
Page 4 of 4
Results 31 - 40 of 40

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country